Mind Medicine (MindMed) Inc. announced that the first patient has been dosed in its Phase 3 Voyage Study for MM120 targeting Generalized Anxiety Disorder.
AI Assistant
MIND MEDICINE (MINDMED) INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.